Alex Delaney-Gesing, Senior Editor

Kelly Voltz, OD, FAAO, FSLS, shares what she wishes she knew before entering optometry.

If approved, pegcetacoplan—an investigational, targeted C3 therapy—will be the first-ever treatment for GA.

The first-of-its-kind alliance and latest phase of AOA's national public awareness campaign focuses on the effects of extended time on digital devices and its impact on eye health.

Current CFO Richard Jones named as interim CEO throughout the search.

A recent study by Orbis International reports that children with myopia experienced significantly higher levels of depression and anxiety than their peers without vision impairment.

Presented during the 2022 ASRS meeting, results find that over 60% of participants could be treated every 4 months at 2 years—an increase from 45% at year 1.

A decade after the conclusion of the NIH-funded AREDS2 study, researchers found that the AREDS2 formula also reduces the risk of lung cancer.

Drug submission of the first water-free therapy took place at the end of June, according to the companies.

The company intends to develop the AcuStream technology for potential use with its current and future front-of-eye therapies, which may include lifitegrast ophthalmic solution for the treatment of dry eye disease.

Mojo Vision's CEO Drew Perkins announced last week that he became the first, and currently only, person to wear the latest prototype of Mojo Lens, an augmented reality-based contact lens.

Bausch + Lomb's Bill Reindel, OD, speaks on highlights from his lecture titled “Evaluation of an Advanced Multi-Purpose Solution for Soft Re-Usable Contact Lenses."

During AOA 2022, Cecelia Koetting, OD, FAAO, shares highlights from her presentation titled "Ocular Surgeries and the Role of the Paraoptometric."

Stuart Richer, OD, PhD, provides an overview of his AOA 2022 presentation titled, "Alzheimer's disease: diagnostic criteria, prevention, and lifestyle management."

During AOA 2022, Mile Brujic, OD, FAAO, shares his advice and best practices for new optometry school grads on how to be financially smart.

The company has received the all-clear for a multinational market launch of Acuvue Oasys Max 1-Day and Acuvue Oasys Max 1-Day multifocal contact lenses.

The Revive custom soft contact lenses are designed with non-ionic material that allows for daily wear for up to 3 months.

Maria Sampalis, OD, discusses streamlining the dry eye process in her practice for optimum efficiency.

A new study has found that having a contact lens regimen makes a difference when removing coronavirus particles, as well as the type of lens care solution that is used.

Jeffrey Anshel, OD, FAAO, offers a sneak peek of his latest book titled "What you must know about eyestrain."

Maria Sampalis, OD, shares what a typical schedule for dry eye patients looks like on a daily and weekly basis at her practice.

The new partnership supports Alcon's Pataday Once Daily Relief Extra Strength eye drops as treatment for eye allergies.

New solution contains 25% more moisture, company says.

This is the second FDA-approved indication for BEOVU; it was initially approved in 2019 for the treatment of wet AMD.

A decision by the FDA is expected in August 2022.

Maria Sampalis, OD, shares how her practices is able to set itself apart from others within the dry eye field.

Mark T. Dunbar, OD, FAAO, shares what he wished he knew before entering the optometric profession.

Investigators from the Sun Yay-Sen University in Guangzhou have created a theranostic device that targets sensing rising fluid pressures within the eye to automatically deliver medication for a glaucoma patient.

The COMET-2 study is the first of three studies in the AR-15512 phase 3 registration program, with topline results expected by the second half of 2023.

Maria Sampalis, OD, continues her dry eye discussion what factors she considers when diagnosing and treating patients.

Daniel G. Fuller, OD, FAAO Dipl., FSLS, shares what he wish he knew before entering the field.